Goldman Sachs’s Ortho Clinical Diagnostics Holdings OCDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-2,191,433
Closed -$40.9M – 6921
2022
Q1
$40.9M Buy
2,191,433
+1,187,486
+118% +$21.4M 0.01% 1449
2021
Q4
$21.5M Buy
1,003,947
+676,700
+207% +$13.3M ﹤0.01% 2052
2021
Q3
$6.05M Buy
327,247
+264,162
+419% +$5.32M ﹤0.01% 3194
2021
Q2
$1.35M Sell
63,085
-481,120
-88% -$9.8M ﹤0.01% 4537
2021
Q1
$10.5M Buy
+544,205
New +$9.6M ﹤0.01% 2526

Other funds holding OCDX

Goldman Sachs's OCDX Position: Q2 2022 in Review

Goldman Sachs sold out of Ortho Clinical Diagnostics Holdings (OCDX) in Q2 2022, closing a stake of 2,191,433 shares — an estimated $40.9M sold.

Goldman Sachs first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $40.9M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

  • Goldman Sachs reported no remaining Ortho Clinical Diagnostics Holdings position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 2,191,433 Ortho Clinical Diagnostics Holdings shares in Q2 2022, an estimated $40.9M.
  • Goldman Sachs first reported a position in Ortho Clinical Diagnostics Holdings in Q1 2021 and held it in 5 quarters.
  • Goldman Sachs's Ortho Clinical Diagnostics Holdings position peaked at $40.9M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.